vimarsana.com

Latest Breaking News On - Mabwell therapeutics - Page 3 : vimarsana.com

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesChristina tartagliaJohn quiselDisc medicine incDrug administrationVerge scientific communicationsTrack designationUnited states foodFast track designationFast trackChief executive officerTransmembrane serine proteaseMabwell therapeuticsPolycythemia veraPrivate securities litigation reform actDiamond blackfan anemia

Phase 3 Adds Three Life Sciences Tenants in San Diego

The 86,000-square-foot lab conversion was completed in June

San diegoUnited statesDel mar heightsSan franciscoJohn hundleyShane poppenTristen schneiderHughes marinoTaylor deberryKidder mathewsGenece healthEstate partnersGenesis del marCamino realMabwell therapeuticsGrant schoneman

FDA clears clinical trial of Mabwell s IL-11 antibody therapy for IPF | Phase 1 trial in Australia testing safety of Mabwell s IL-11 inhibitor in healthy adults

Mabwell Therapeutics has been cleared by the FDA to launch a clinical trial testing 9MW3811, its injectable treatment for IPF and cancer.

Drug administrationNational medical products administrationMabwell therapeuticsLassen therapeutic

Disc Medicine Opco : Reports First Quarter 2023 Financial Results and Provides Business Update - Form 8-K

Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic. | May 15, 2023

Suzanne messereJohn quiselExchange commissionVerge scientific communicationsCongress onEuropean hematology associationBain capital life sciencesDisc medicine incDevelopment expensesDisc medicine reports first quarterProvides businessMabwell therapeuticsBain capital lifeChief executive officerBusiness highlightsUpcoming milestones

Disc Medicine Opco : Reports Full Year 2022 Financial Results and Provides Business Update - Form 8-K

Disc Medicine, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic. | March 31, 2023

United statesSuzanne messereArix bioscienceJohn quiselEuropean committee for orphan medical productsNovo holdingsEuropean hematology association annual congressAtlas ventureDisc medicine incDevelopment expensesVerge scientific communicationsBain capital life sciencesDrug administrationAmerican society of hematology annual meetingExchange commissionDisc medicine reports full year

vimarsana © 2020. All Rights Reserved.